Alto Neuroscience, Inc.

ANRO NYSE SEC CIK 1999480
Follow Alto Neuroscience Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$25.1M −77.2% vs same quarter last year
EPS, diluted −$0.54 −3.8% vs same quarter last year
Operating cash flow −$20.8M −109.3% vs same quarter last year
Operating income −$27.2M −82.1% vs same quarter last year
Net income by quarter
−$15.2M
−$15.2M
−$17.7M
−$14.2M
−$16.2M
−$26.2M
−$27.6M
−$25.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$80M−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$63.2M
FY24−$61.4M
FY23−$36.3M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$51.8M
FY24−$49.5M
FY23−$33.9M
FY22-